Peptide Vaccine for Rare Liver Cancer Achieves 75% Disease Control in Phase 1 Trial
A Phase 1 trial published in Nature Medicine showed that FLC-Vac, a therapeutic peptide vaccine targeting the DNAJ-PKAc fusion protein in fibrolamellar hepatocellular carcinoma, combined with nivolumab and ipilimumab achieved 75% disease control (9/12 patients) and 25% partial response rate. All responders showed tumor-specific T cell responses.